Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a spinout of George Church’s Lab at Harvard Medical School working on targeting the driver of age-related disease through the use of novel gene therapies. Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Daniel received his M.B.A. from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.